Oxford Pharmascience completes next step in Safestat programme

Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin.

Oxford Pharmascience, a speciality pharmaceutical company, has successfully completed the formulation development for its Safestat drugs, Atorvastatin and Simvastatin.

The developments continue the company's Safestat programme, which aims to re-formulate the widely used molecules of atorvastatin and simvastatin into doses up to four times lower than the original dose, but with the same lipid-lowering properties as the original higher dose.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience said: "Completion of formulation development is a first important milestone in the Safestat programme and we are now ready to proceed to manufacture of GMP products for use in proof of concept clinical trials during 2013."

The company said it has now developed and optimised formulations of both atorvastatin and simvastatin and proven in-vitro release under simulated human conditions.

The share price rose 29.91% to 3.48p by 14:10.

NR

Recommended

Best junior stocks and shares ISA platforms
Isas

Best junior stocks and shares ISA platforms

A junior stocks and shares ISA is a great way to save for your child tax-efficiently. But it can be confusing deciding which investment platform to ch…
25 Nov 2022
Share tips of the week – 25 November
Share tips

Share tips of the week – 25 November

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
25 Nov 2022
Investing in a recession: 5 moves investors should make now
Investment strategy

Investing in a recession: 5 moves investors should make now

As we enter a recession, here’s what investors should do with their portfolios.
23 Nov 2022
It’s time to focus on Fuller’s
Share tips

It’s time to focus on Fuller’s

The pub sector has had a torrid two years, but this group is resilient and poised to prosper. We take a closer look at Fuller’s.
21 Nov 2022

Most Popular

Wood-burning stove vs central heating ‒ which is cheapest?
Personal finance

Wood-burning stove vs central heating ‒ which is cheapest?

Demand for wood-burning stoves has surged as households try to reduce their heating costs this winter. But how does a wood burner compare with central…
21 Nov 2022
Fan heater vs oil heater – which is cheaper?
Personal finance

Fan heater vs oil heater – which is cheaper?

Sales of portable heaters have soared, as households look to cut their energy costs. But which is better: a fan heater or an oil heater? We put them t…
21 Nov 2022
Best savings accounts – November 2022
Savings

Best savings accounts – November 2022

Interest rates on cash savings are making a comeback. We look at the best savings accounts on the market now
28 Nov 2022